KLOW Blend (GHK-Cu / TB-500 / BPC-157 / KPV 50/10/10/10mg)

KLOW Blend (GHK-Cu / TB-500 / BPC-157 / KPV 50/10/10/10mg) — Research Overview

KLOW is a research-grade quad-peptide formulation combining GHK-Cu (50mg), TB-500 (10mg), BPC-157 (10mg), and KPV (10mg) in a single lyophilized vial. Each compound targets a distinct biological pathway with minimal overlap, allowing researchers to examine four separate mechanisms simultaneously.

What the Research Shows

GHK-Cu has over 50 years of published research documenting collagen synthesis stimulation, matrix metalloproteinase modulation, angiogenesis promotion, and modulation of over 4,000 human genes (DOI: 10.3390/ijms19071987).

BPC-157 has over 100 preclinical studies documenting VEGFR2 activation and Akt-eNOS signaling (DOI: 10.1007/s00109-016-1488-y).

TB-500 operates through actin polymerization and cytoskeletal regulation to promote cell migration (PMID: 17084833).

KPV is a tripeptide derived from alpha-MSH studied for intracellular NF-kB pathway modulation in mucosal tissue models.

None of the four compounds are approved by the FDA for human or veterinary therapeutic use. All primary findings are preclinical.

Quality Documentation

• 99%+ purity — HPLC and Mass Spectrometry verified
• GHK-Cu 50mg + TB-500 10mg + BPC-157 10mg + KPV 10mg per vial
• Batch-specific COA included with every order
• USA tested and fulfilled

Read the GHK-Cu research overview

Read the BPC-157 and TB-500 research overview

For laboratory research purposes only. Not for human or veterinary consumption.